What is Gland Pharma Ltd (GLAND) share price today?

Gland Pharma Ltd (GLAND) is listed on the NSE. Visit VestAI at https://www.vestai.io/stocks/GLAND for the latest live price, technical analysis, and AI-powered insights.

How to analyse GLAND stock?

VestAI provides comprehensive GLAND stock analysis including RSI, MACD, Bollinger Bands, SMA trend, ROCE, debt-to-equity ratio, and smart money holdings by superstar investors.

What sector is Gland Pharma Ltd in?

Gland Pharma Ltd (GLAND) is in the Healthcare sector, Pharmaceuticals industry on the NSE.

Gland Pharma Ltd

Name: Gland Pharma Ltd (GLAND) Financial Metrics
Creator: VestAI

GLAND

NSE· Healthcare

₹2,449.00

-80.40 (-3.18%)

Updated 11:26 am IST

52W Low · ₹1,573.6052W High · ₹2,573.50

Near 52W High

Market Cap

₹37495.33L Cr

Volume

3.27L

Prev Close

₹2,529.40

ISIN

INE068V01023

Orion Score

Fundamentals-based quality & risk · not a recommendation

60/100

Watch

Gland Pharma Ltd scores 60/100 (Watch) on the Orion Score — moderate business quality (60), moderate growth (58), strong balance-sheet safety (88) and rich valuation (28). A fundamentals-based quality & risk score, not a buy/sell recommendation.

Quality

Growth

Safety

Value

Full Orion analysis

Risk checks

Short track record (4 yrs of data)

Forensic accounting

Piotroski F 5/9Altman Z Safe(10.32)Beneish M Clean(-2.35)

Piotroski F = fundamental health (0–9, higher is better) · Altman Z = bankruptcy / distress risk · Beneish M = earnings-manipulation check

Technical / Momentum

Price Trend

56/100

Neutral

Technical momentum companion — separate from the fundamentals-based Orion Score.

Unlock with Pro

Upgrade →

VestAI Stock Score

VALUATION

Low Debt

D/E 0.03x — lean balance sheet

QUALITY

Average

ROCE 11.1% — decent returns

MOMENTUM

Neutral

RSI 59.5 — consolidating

Price Chart

SMA 20

SMA 50

SMA 200

Key Fundamentals

Q4 FY2026

P/E Ratio: 36.50
ROCE: 11.06%
ROE (1Y): 10.53%
D/E Ratio: 0.03x
OPM: 23.20%
TTM EPS: ₹62.28
Dividend Yield: 88.00%
Qtrly Sales: ₹1,742.79 Cr
Qtrly Profit: ₹366.68 Cr

Technical Signals

Quarterly Results

Revenue & Profit in ₹ Crores

Revenue Net Profit

Quarter	Revenue	Net Profit	OPM	EPS
Q4 2026	₹1,742.79	₹366.68	23.2%	₹22.23
Q3 2026	₹1,695.36	₹261.48	19.3%	₹15.87
Q1 2026	₹1,505.62	₹215.48	17.7%	₹13.08
Q4 2025	₹1,424.91	₹186.54	17.7%	₹11.32
Q3 2025	₹1,384.05	₹204.69	19.1%	₹12.42

Annual P&L

Revenue & Profit in ₹ Crores (Yearly)

Revenue Net Profit

Year	Revenue	Net Profit	EBITDA	OPM
FY 2026	₹6,430.65	₹1,027.32	₹1,921.53	18.8%
FY 2025	₹5,616.5	₹698.53	₹1,482.53	15.9%
FY 2024	₹5,641.73	₹772.46	₹1,498.9	17.7%
FY 2023	₹3,591.86	₹781.04	₹1,207.61	24.2%

Peer Comparison — Healthcare

Top companies in the same sector by market cap

Company	Mkt Cap	P/E	ROCE	ROE	D/E	OPM
GLAND ★	₹37,495 Cr	36.50	11.06%	10.53%	0.03x	23.20%
SUNPHARMASun Pharmaceutical Industries	₹4,27,609 Cr	37.32	15.73%	14.72%	0.06x	18.90%
MAXHEALTHMax Healthcare Institute	₹95,110 Cr	66.21	11.94%	14.33%	0.32x	22.56%
AUROPHARMAAurobindo Pharma Limited	₹90,029 Cr	25.94	12.55%	9.93%	0.21x	15.11%
ABBOTINDIAAbbott India Limited	₹57,724 Cr	36.63	36.14%	34.46%	0.04x	27.01%
AJANTPHARMAjanta Pharma Limited	₹41,836 Cr	39.55	27.99%	25.39%	0.06x	51.40%

Balance Sheet

All values in ₹ Crores

Metric	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	₹11,224.92	₹10,661.25	₹8,777.53	₹7,833.62
Equity	₹9,150.74	₹8,723.84	₹7,958.72	₹7,157.62
Total Debt	₹313.73	₹372.17	₹4.45	₹4.74
Cash	₹2,556.19	₹357.09	₹1,908.89	₹294.82
Net Debt	—	—	—	—
Working Capital	₹5,218.09	₹4,246.79	₹6,171.68	₹5,270.05

Shareholding Pattern

Q1 FY2027

Promoter

51.77%

FII

19.94%

DII

16.31%

Public

11.98%

Quarter-over-Quarter Trend

Quarter	Promoter	FII	DII	Public
Q1 FY2027	51.77% ↓	19.94% ↑	16.31% ↓	11.98% ↑
Q3 FY2026	51.83%	7.58% ↓	32.99% ↑	7.62%
Q2 FY2026	51.83%	7.9% ↑	32.63% ↓	7.63% ↓
Q1 FY2026	51.83%	7.39% ↑	32.86% ↓	7.93% ↓
Q4 FY2025	51.83%	6.9% ↑	33.27% ↓	8% ↓
Q3 FY2025	51.83%	5.04% ↑	34.8% ↓	8.33%
Q2 FY2025	51.83%	4.48% ↓	35.37% ↑	8.33% ↓
Q1 FY2025	51.83%	6.88%	32.83%	8.46%

Corporate Actions

Ex-Date	Action	Details
2026-08-11	DIVIDEND	Dividend - Rs 20 Per Sh

Funds Holding This Stock

112 mutual fund schemes

DSP Healthcare Fund Direct GrowthDSP

6.26%

₹207 Cr

UTI Healthcare Fund Direct GrowthUTI

3.98%

₹52 Cr

ICICI Prudential MNC Fund Direct GrowthICICI_PRUDENTIAL

3.75%

₹65 Cr

UTI MNC Fund Direct GrowthUTI

3.56%

₹97 Cr

LIC MF Healthcare Fund Direct GrowthLIC

3.55%

₹3 Cr

Aditya Birla Sun Life MNC Fund Direct GrowthBIRLA_SUN_LIFE

3.06%

₹99 Cr

Tata Nifty MidSmall Healthcare Index Fund Direct GrowthTATA

2.98%

₹5 Cr

Motilal Oswal Nifty MidSmall Healthcare Index Fund Direct GrowthMOTILAL_OSWAL

2.98%

₹1 Cr

SBI Healthcare Opportunities Fund Direct Plan GrowthSBI

2.96%

₹135 Cr

Mirae Asset Focused Fund Direct GrowthMIRAE_ASSET

2.82%

₹184 Cr

Analyse GLAND with Orion AI

Ask: "Is Gland Pharma Ltd stock a good buy right now?" — Get RSI, MACD, ROCE + AI recommendation

Analyse with Orion

Want more insights like this?

Get free stock analysis, market insights, and investment ideas delivered to your inbox.

No spam. Unsubscribe anytime.

About Gland Pharma Ltd (GLAND) Stock

Gland Pharma Ltd is listed on the NSE under the Healthcare sector, Pharmaceuticals industry. ISIN: INE068V01023. Track live share price, technical analysis, RSI, MACD, PE ratio, and smart money holdings on VestAI — India's AI-powered stock analysis platform.